Valneva has announced positive outcomes from its Phase III trial of the single-shot IXCHIQ chikungunya virus vaccine in ...

YolTech Therapeutics is set to commence a trial of its in vivo gene editing therapy, YOLT-204, aimed at treating TDT.

The study found that the number of advanced therapy Phase I trials in the UK nearly doubled since the same time in 2023.

To observe the effects of coffee consumption on HNC risk, a study published in Cancer utilised pooled data from the INHANCE ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable.

Results from the single-arm trial saw 63.5% of patients able to avoid the symptoms of Atrial fibrillation over the course of ...

The FDA has granted approval for Zydus to proceed with the Phase II(b) trial of Usnoflast for amyotrophic lateral sclerosis (ALS) treatment.

The new pan-European group of 73 regulators, companies and trial sites is backed by €66.8m in funding with a six-year goal.

Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment.

Palisade Bio has begun the multiple ascending dose (MAD) cohorts of its ongoing Phase Ia/b trial of PALI-2108 for ulcerative ...

Avacta Therapeutics has reported outcomes from the Phase Ia trial of AVA6000, a drug candidate for solid tumours.

Sen-Jam Pharmaceutical has reported positive preliminary outcomes from its Phase II trial of SJP-002C to treat upper ...